Celldex Therapeutics (CLDX) Change in Accured Expenses (2010 - 2026)

Celldex Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 124.83% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at $10.3 million (down 35.0% YoY), while the FY2025 annual figure was $11.0 million, down 5.18% from the prior year.
• Change in Accured Expenses was -$1.4 million for Q1 2026 at Celldex Therapeutics, down from $4.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $16.4 million in Q4 2024 to a low of -$6.0 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $1.4 million across 5 years, with a median of -$604000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses surged 2577.53% in 2024, then tumbled 451.69% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $2.0 million in 2022, then tumbled by 133.05% to -$663000.0 in 2023, then soared by 2577.53% to $16.4 million in 2024, then tumbled by 71.99% to $4.6 million in 2025, then sank by 129.52% to -$1.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), $4.6 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.